IL6 and hepatocellular carcinoma: AKR1C3 participates in NF-κB signaling and IL6/STAT3 pathway, resulting in cell proliferation and metastasis in hepatocellular carcinoma (HCC) cells, while treatment with the AKR1C3 inhibitors could suppress tumor growth and promote cell death [15].